Oncology based Indications

Acquisition of ArQule; Synthorx; and Zentalis nabs a raise

Feb 14, 2020

Merck is set to complete the already planned purchase of the ArQule for USD 2.7 Billion. Under the terms of the agreement, Merck will pay USD 20 for each share in cash for ...

Notizia

Feb 6, 2020

FDA gives thumbs-up to Balversa The U.S. FDA has granted approval of Balversa (erdafitinib) to Belgium-based Janssen Pharmaceutica, for the treatment of advanced or metasta...

Notizia

Apr 16, 2020

Selumetinib gets the U.S. Breakthrough Therapy Designation Selumetinib- an investigational drug, for the treatment of pediatric patients aged three years and above sufferin...

Notizia

Feb 6, 2020

Stemline gives in-licenses global rights to SL-1001 Stemline Therapeutics, Inc. is a biopharmaceutical company focused on development and commercialization of novel oncolog...

A helping hand in treatment of CRC

Feb 5, 2020

Patients suffering from Colorectal Cancer (CRC) usually gets affected with distant organ metastases spreading the tumor to other parts of the body. Patients with unresectab...

Neuroendocrine tumors (NETs): The complex group of tumors

Jul 2, 2020

Neuroendocrine tumors (NETs) consists of complex group of tumors that develop predominantly in the digestive or respiratory tracts, but can occur in many areas of the body....

4D Molecular Therapeutics raises; Arvinas slates for IPO; Sutro ruminates for $ 75M; Emergent BioSolutions remunerates Narcan maker

Jun 19, 2020

Gene therapy company 4D Molecular Therapeutics raises USD 90 Million to collaborate with AstraZeneca and Roche for moving gene therapies into clinical testing 4D Molecular ...